The dual-action agent LCZ696 blocks the angiotensin II receptor (via a valsartan moiety) and inhibits neprilysin (via an AHU377 moiety). In a phase II trial, this drug “demonstrated superior ...

Unfortunately neprilysin can't enter the brain from the ... levodopa reduced beta-amyloid deposition and improved cognitive function." This is all very promising, but plenty of questions remain.